Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ANIX Anixa Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: ANIX
Price (delayed)
$2.84
Market cap
$91.48M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.38
Enterprise value
$89.79M
Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type
Highlights
The debt has increased by 48% YoY but it has decreased by 3.9% from the previous quarter
The net income has declined by 4.6% year-on-year but it has increased by 2.8% since the previous quarter
The company's quick ratio fell by 41% YoY and by 4.2% QoQ
The equity has contracted by 32% YoY and by 10% from the previous quarter
Key stats
What are the main financial stats of ANIX
Market
Valuations
Earnings
Shares outstanding
32.21M
Market cap
$91.48M
Enterprise value
$89.79M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.69
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$13.14M
Net income
-$12.13M
EBIT
-$12.13M
EBITDA
-$12.1M
Free cash flow
-$7.98M
Per share
Balance sheet
Liquidity
EPS
-$0.38
EPS diluted
-$0.38
Free cash flow per share
-$0.25
Book value per share
$0.5
Revenue per share
$0
TBVPS
$0.53
Total assets
$16.98M
Total liabilities
$2.07M
Debt
$221,000
Equity
$16.07M
Working capital
$14.88M
Debt to equity
0.01
Current ratio
8.89
Quick ratio
8.27
Net debt/EBITDA
0.14
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-60.4%
Return on equity
-64.1%
Return on invested capital
-72%
Return on capital employed
-80.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANIX stock price
How has the Anixa Biosciences stock price performed over time
Intraday
0%
1 week
10.51%
1 month
7.98%
1 year
20.34%
YTD
22.41%
QTD
-0.7%
Financial performance
How have Anixa Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.14M
Net income
-$12.13M
Gross margin
N/A
Net margin
N/A
The net income has declined by 4.6% year-on-year but it has increased by 2.8% since the previous quarter
ANIX's operating income is up by 3.4% since the previous quarter
Price vs fundamentals
How does ANIX's price correlate with its fundamentals
Growth
What is Anixa Biosciences's growth rate over time
Valuation
What is Anixa Biosciences stock price valuation
P/E
N/A
P/B
5.69
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ANIX's EPS is down by 2.7% year-on-year but it is up by 2.6% since the previous quarter
The equity has contracted by 32% YoY and by 10% from the previous quarter
The price to book (P/B) is 19% higher than the 5-year quarterly average of 4.8 and 7% higher than the last 4 quarters average of 5.3
Efficiency
How efficient is Anixa Biosciences business performance
Anixa Biosciences's return on invested capital has decreased by 38% YoY and by 9% QoQ
The return on equity has declined by 36% year-on-year and by 7% since the previous quarter
The company's return on assets fell by 33% YoY and by 6% QoQ
Dividends
What is ANIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANIX.
Financial health
How did Anixa Biosciences financials performed over time
The company's quick ratio fell by 41% YoY and by 4.2% QoQ
The current ratio has declined by 38% year-on-year and by 4.9% since the previous quarter
The debt is 99% less than the equity
The debt has increased by 48% YoY but it has decreased by 3.9% from the previous quarter
The equity has contracted by 32% YoY and by 10% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.